Comparative Pharmacology
Head-to-head clinical analysis: DOXY 200 versus SOLODYN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DOXY 200 versus SOLODYN.
DOXY 200 vs SOLODYN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Doxycycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA from binding to the mRNA-ribosome complex, and thus inhibiting peptide chain elongation. It is bacteriostatic and active against a broad range of gram-positive and gram-negative bacteria, as well as atypical organisms.
Solodyn (minocycline hydrochloride) is a tetracycline antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing the addition of amino acids to the growing peptide chain.
200 mg orally once daily or 100 mg orally every 12 hours.
1 mg/kg orally once daily as extended-release tablets; not to exceed 100 mg/day. Alternatively, 1 mg/kg orally once daily as immediate-release tablets; not to exceed 100 mg/day.
None Documented
None Documented
Terminal elimination half-life: 18–22 hours in adults with normal renal function; prolonged in renal impairment (up to 40 hours).
Terminal elimination half-life: 11-22 hours (mean ~16 hours). Clinically, steady-state reached in 3-4 days; half-life prolonged in renal impairment.
Renal: 40% unchanged via glomerular filtration; Biliary/fecal: 20–25% as active drug and metabolites; remainder as inactive metabolites.
Primarily renal (40-70% unchanged) via glomerular filtration; significant biliary/fecal (20-30%) as unchanged drug and metabolites. Enterohepatic recirculation occurs.
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic